Celgene Corporation(NASDAQ:CELG) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $2.75B. Analysts estimated a revenue of $2.70B. Earnings per share were $1.44. Analysts had estimated an EPS of $1.38.
In a different note, Stifel Nicolaus said it Initiates Coverage on Celgene Corporation, according to a research note issued on Jul 15, 2016. The shares have been rated ‘Buy’ by the firm. On Jun 1, 2016, BTIG Research said it Downgrades its rating on Celgene Corporation. The shares have been rated ‘Neutral’ by the firm.
Celgene Corporation (CELG) made into the market gainers list on Thursdays trading session with the shares advancing 0.11% or 0.13 points. Due to strong positive momentum, the stock ended at $116.27, which is also near the day’s high of $117.452. The stock began the session at $116.61 and the volume stood at 73,76,899 shares. The 52-week high of the shares is $133.5903 and the 52 week low is $92.98. The company has a current market capitalization of $90,123 M and it has 77,51,14,700 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jun 22, 2016, Robert J Hugin (director officer ) sold 75,000 shares at $100.16 per share price.Also, On Apr 5, 2016, Gilla Kaplan (director) sold 15,967 shares at $101.84 per share price.On Mar 7, 2016, Michael W Bonney (director) purchased 2,000 shares at $103.01 per share price, according to the Form-4 filing with the securities and exchange commission.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.